Abstract
Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Current Drug Safety
Title: Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism
Volume: 6 Issue: 2
Author(s): Peter Vestergaard and Susanna vid Streym Thomsen
Affiliation:
Keywords: Alphacalcidol, calcitriol, cinacalcet, hyperparathyroidism, parathyroid hormone, paricalcitol, uremia, vitamin D, pregnancy
Abstract: Hyperparathyroidism is a condition with elevated parathyroid hormone (PTH). The increase may be due to a) primary hyperparathyroidism which is caused by adenoma of one or more parathyroid glands or hyperplasia of all four glands, b) secondary hyperparathyroidism, which may be caused by deficiency in vitamin D or uremia, and 3) tertiary hyperparathyroidism, which most often is the result of a long-standing, severe secondary hyperparathyroidism, which has turned autonomous once the cause of the secondary hyperparathyroidism has been removed. Many new treatment options have been introduced in recent years. Cinacalcet is a calcium sensing receptor agonist, which by stimulating the receptor decreases PTH and calcium levels. It may be used in primary hyperparathyroidism, secondary hyperparathyroidism caused by uremia, which may not be controlled with calcium and activated vitamin D. It may also be used in tertiary hyperparathyroidism. Newer analogues of vitamin D such as paricalcitol have also been introduced, which may have an advantage over traditional compounds such as alphacalcidol and calcitriol.
Export Options
About this article
Cite this article as:
Vestergaard Peter and vid Streym Thomsen Susanna, Medical Treatment of Primary, Secondary, and Tertiary Hyperparathyroidism, Current Drug Safety 2011; 6 (2) . https://dx.doi.org/10.2174/157488611795684703
DOI https://dx.doi.org/10.2174/157488611795684703 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis
Current Molecular Pharmacology Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Regulation and Function of Rankl in Arterial Calcification
Current Pharmaceutical Design Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Postmenopausal Osteoporosis and Aerobic Exercise: A Review of the Literature
Current Rheumatology Reviews Patents Review in siRNA Delivery for Pulmonary Disorders
Recent Patents on Drug Delivery & Formulation Alternative Gene Therapy Strategies for the Repair of Craniofacial Bone Defects
Current Gene Therapy The Potential use of Dendritic Cell-based Immunotherapy for Treatment of Pancreatic Cancer
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Current Patents on Osteoinductive Molecules for Bone Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Recent Updates on the Calcium-Sensing Receptor as a Drug Target
Current Medicinal Chemistry The Role of Vitamin D in Gastrointestinal Diseases: Inflammation, Gastric Cancer, and Colorectal Cancer
Current Medicinal Chemistry Bone Morphogenetic Protein-Smad Pathway as Drug Targets for Osteoporosis and Cancer Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances Using Supercritical Fluid Techniques for Pulmonary Administration of Macromolecules via Dry Powder Formulations
Drug Delivery Letters Patent Selections
Recent Patents on Biomedical Engineering (Discontinued) New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Prostaglandin E2 Receptors as Potential Bone Anabolic Targets – Selective EP4 Receptor Agonists
Current Molecular Pharmacology Subject Index To Volume 8
Current Pharmaceutical Design Strategies that Target Tight Junctions for Enhanced Drug Delivery
Current Pharmaceutical Design